TITLE

A Rational Approach to Drug Therapy of Type 2 Diabetes Mellitus

AUTHOR(S)
Chehade, J.M.; Mooradian, A.D.
PUB. DATE
July 2000
SOURCE
Drugs;Jul2000, Vol. 60 Issue 1, p95
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Several new pharmacological agents have recently been developed to optimise the management of type 2 (non-insulin-dependent) diabetes mellitus. The aim of this article is to briefly review the various therapeutic agents available for management of patients with type 2 diabetes mellitus and to suggest a potential approach to drug selection. There are three general therapeutic modalities relevant to diabetes care. The first modality is lifestyle adjustments aimed at improving endogenous insulin sensitivity or insulin effect. This can be achieved by increased physical activity and bodyweight reduction with diet and behavioural modification, and the use of pharmacological agents or surgery. This first modality is not discussed in depth in this article. The second modality involves increasing insulin availability by the administration of exogenous insulin, insulin analogues, sulphonylureas and the new insulin secretagogue, repaglinide. The most frequently encountered adverse effect of these agents is hypoglycaemia. Bodyweight gain can also be a concern, especially in patients who are obese. The association between hyperinsulinaemia and premature atherosclerosis is still a debatable question. The third modality consists of agents such as biguanides and thiazolidinediones which enhance insulin sensitivity, or agents that decrease insulin requirements like the α-glucosidase inhibitors. Type 2 diabetes mellitus is a heterogeneous disease with multiple underlying pathophysiological processes. Therapy should be individualised based on the degree of hyperglycaemia, hyperinsulinaemia or insulin deficiency. In addition, several factors have to be considered when prescribing a specific therapeutic agent. These factors include efficacy, safety, affordability and ease of administration.
ACCESSION #
9592994

 

Related Articles

  • Intensive blood glucose therapy for type 2 diabetics.  // Modern Medicine;Jan99, Vol. 67 Issue 1, p22 

    Discusses the abstract `Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes' by the United Kingdom Prospective Diabetes Study Group published in the September 12, 1998 issue of `Lancet'...

  • Oral hypoglycemic agents in the treatment of type II diabetes. Tal, Alexander // American Family Physician;11/1/1993, Vol. 48 Issue 6, p1089 

    Discusses sulfonylureas and their use as oral hypoglycemic agents in the treatment of non-insulin-dependent (type II) diabetes. Pharmacologic properties; Comparison of oral sulfonylurea drugs; Mechanism of action; Therapeutic results; Side effects; Drug interactions; Biguanides and other drugs.

  • Other.  // Medical Marketing & Media;Dec2011, Vol. 46 Issue 12, p45 

    A preview of the drug Bydureon from Amylin Pharmaceuticals Inc., to be used for the treatment of type 2 diabetes and which has completed six months of its clinical trials, is presented.

  • Exenatide: from the Gila monster to the pharmacy. Triplitt, Curtis; Chiquette, Elaine // Journal of the American Pharmacists Association: JAPhA;Jan/Feb2006, Vol. 46 Issue 1, p44 

    Objective: To explain the incretin concept and review the pharmacology and clinical utility of exenatide (Byetta-Amylin; Lilly), a new agent for the treatment of patients with type 2 diabetes mellitus, and provide pharmacists with information necessary for counseling patients in the...

  • Treatment of type II diabetes. Nattrass, Malcolm // British Medical Journal (Clinical Research Edition);4/19/1986, Vol. 292 Issue 6527, p1033 

    Focuses on the clinical management of type II diabetes. Mechanism of action of sulphonylureas; Shift from long to a short acting drug among older patients; Control of hypoglycemia by administering oral hypoglycemic agents.

  • Clinical pharmacokinetics: brief reports.  // Drugs & Therapy Perspectives;Apr2006, Vol. 22 Issue 4, p16 

    Advances in treatment for type 2 diabetes mellitus have seen an increase in polypharmacy. A higher incidence of hypoglycaemia may occur when multiple antihyperglycaemic agents are used. Potential interactions between oral glucose-lowering agents and other drugs (e.g. those that are widely...

  • First reports of serious adverse drug reactions in recent weeks.  // Drugs & Therapy Perspectives;Apr2006, Vol. 22 Issue 4, p16 

    Advances in treatment for type 2 diabetes mellitus have seen an increase in polypharmacy. A higher incidence of hypoglycaemia may occur when multiple antihyperglycaemic agents are used. Potential interactions between oral glucose-lowering agents and other drugs (e.g. those that are widely...

  • Effects of drug-drug interactions involving oral antihyperglycaemics are, with the exception of hypoglycaemia, mostly clinically unimportant.  // Drugs & Therapy Perspectives;Apr2006, Vol. 22 Issue 4, p18 

    Advances in treatment for type 2 diabetes mellitus have seen an increase in polypharmacy. A higher incidence of hypoglycaemia may occur when multiple antihyperglycaemic agents are used. Potential interactions between oral glucose-lowering agents and other drugs (e.g. those that are widely...

  • chlorpropamide.  // Royal Society of Medicine: Medicines;2002, p152 

    The article provides information on the drug chlorpropamide. It is a sulphonylurea which is used in diabetic treatment of Type II diabetes mellitus. It works by augmenting what remains of production in the pancreas and its effect lasts longer than that of most similar drugs. Unusually for a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics